Anticoagulation monitoring is done by monitoring the ACT (Activated Clotting Time) with an objective greater than 300 s. Until now, treatment with direct oral anticoagulant (for the prevention of thromboembolic events of atrial fibrillation) was interrupted a few days before the procedure in order to limit the risk of per-procedural bleeding. However, 3 recent randomized studies concerning the 3 DOACs available suggest that treatment should not be interrupted during the entire operative period. The operation therefore takes place under double anticoagulation with a direct oral anticoagulant and unfractionated heparin. Under these conditions, ACT monitoring can no longer be considered a reliable means of measuring the level of anticoagulation. It was therefore necessary to explore the hemostasis of these patients in a broad way in order to avoid any risk of overdose of UFH (Unfractionated Heparin) during the procedure.
Study Type
OBSERVATIONAL
Enrollment
15
Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg
Strasbourg, France
Study of hemorrhagic and thrombotic complications and correlation with the various laboratory tests
Time frame: Files analysed retrospectively from January 01, 2019 to December 31, 2019 will be examined]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.